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MinimodelingTo elucidate the histological events that follow administration of eldecalcitol, a second-generation of vitamin D
analog currently awaiting approval as a drug for treatment of osteoporosis, we employed the ovariectomy
(OVX) rat model. OVX rats received vehicle or 30 ng/kg of eldecalcitol, and sham-operated animals received
vehicle only. Rats were sacriﬁced after 12 weeks and had their femora and tibiae removed and processed for
histochemical and histomorphometrical analyses. When compared with OVX group, osteoclastic number and
bone resorption parameters were signiﬁcantly reduced in eldecalcitol-treated rats, accompanied by decreased
bone formation parameters. The preosteoblastic layer, with which osteoclastic precursors interact for mutual
differentiation, was poorly developed in the eldecalcitol group, indicating less cell-to-cell contact between
preosteoblasts and osteoclast precursors. Interestingly, eldecalcitol did promote a type of focal bone formation
that is independent of bone resorption, a process known as bone minimodeling. While the number of ED-1-
positive macrophages was higher in the bone marrow of treated rats, though osteoclastic number was
deceased. Taken together, our ﬁndings suggest that eldecalcitol stimulates preosteoblastic differentiation
rather than their proliferation, which in turn may prevent or diminish cell-to-cell contact between
preosteoblasts and osteoclastic precursors, and therefore, lead to lower osteoclast numbers and decreased
bone resorption.ai Pharmaceutical Co., Ltd. The
ental Biology of Hard Tissue,
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x: +81 11 706 4225.
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Vitamin D metabolism plays an essential role in regulation
of mineral and bone homeostasis [1]. The active form of 1α,25-
dihydroxyvitamin D3 (1α,25-(OH)2D3), acts through the vitamin D
receptor (VDR) present in target organs such as the intestines, kidney
and parathyroid glands. It stimulates calcium absorption and reab-
sorption while blocking both the synthesis and secretion of another
essential regulator of mineral balance, the parathyroid hormone
(PTH) [2]. VDR has also been found in osteoblasts and osteoclasts,
suggesting that vitamin D may directly affect the skeleton [3,4]. In
bone, the hormone is important in at least two different ways: ﬁrst, it
interacts with the VDR in osteoblastic cells and regulates osteoclastic
activity via the osteoprotegerin (OPG)/receptor activator nuclearfactor kB (RANK)/RANK ligand (RANKL) system [5]; second, it secures
a supersaturated state of calcium–phosphorus products in the blood,
which indirectly enables osteoid mineralization [6]. Vitamin D
deﬁciency may lead to exacerbated bone resorption as a result of
increases in osteoclast number and activity, and may also cause a type
of bone mineralization defect known as rickets in children and
osteomalacia in adults [7]. Interestingly, 1α,25-(OH)2D3was shown to
promote osteoclastic bone resorption in culture [8] and in vivo [9]
and to enhance the expression of RANKL on bonemarrow stromal cells
[10].
Despite its good acceptance in the management of conditions like
psoriasis [11] and cancers [12], the use of vitamin D in the treatment
of osteoporosis has been hindered due to its calcemic activity and the
notion that the hormone drives osteoclastic bone resorption [13–15].
However, there have been reports showing that the therapeutic
effect of active vitamin D can be dissociated from the one on calcium
absorption [16] and that it is mostly related to suppression of bone
resorption due to decreases in the pool of osteoclast precursors
[17,18]. A recent theory based on previous reports of the conversion of
25-hydroxyvitamin D into 1α,25-dihydroxyvitamin D3 by osteoblasts
in vitro [19,20] suggests that vitamin D may be metabolized in the
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of vitamin D administered but calcium absorption reaches a plateau
once normalized by a small dose of vitamin D [21] suggests the
existence of a safer, side effect-free therapeutic window for vitamin D
and its analogs.
Many attempts have been made to synthesize a compound that
would retain only the differentiation and anti-proliferative effects
of 1α,25-(OH)2D3, thus allowing for safer usage and less side effects
[22,23]. Eldecalcitol, formerly known as ED-71, is an analog of 1α,25-
(OH)2D3 bearing a hydroxypropyloxy residue at the 2β position
that was developed in the early 80s and is currently awaiting approval
as a drug for treatment of osteoporosis in Japan [24,25]. It has been
reported that eldecacitol lowered biochemical and histological
parameters of bone resorption in a rat ovariectomized (OVX) model
of osteoporosis [26] and that its effects on bone were observed
without sustained hypercalcemia or hypercalciuria [27].
Examinations focusing on the effects of vitamin D analogs at the
tissue level have been relatively neglected despite the therapeutic
potential of these compounds for the treatment of bone diseases. A
recent report involving bone marrow ablation showed that eldecalci-
tol may promote bone formation and angiogenesis in addition
to inhibiting bone resorption [23]. Further data on the histological
subtleties and on the interplay among bone cells after eldecalcitol
treatment are not yet available. In the present study, we used histo-
logical, histochemical, histomorphometrical and ultrastructural ana-
lyses as tools for investigating the tissue events following the
administration of eldecalcitol in OVX rats.
Materials and methods
Animals, protocol for eldecalcitol administration, and tissue processing
All animal experiments were approved by the Institutional Animal
Care and Use Committee of Chugai Pharmaceutical Co., Ltd., Niigata
University and Hokkaido University, and were conducted in accor-
dance with accepted standards of humane animal care. Eight-months
old Crl:CD(SD)(IGS) rats were obtained from Charles River Laborato-
ries Japan, Inc., and acclimated until 11 months of age under standard
laboratory conditions (23±3 °C, humidity 35%–75%, light–dark cycle
12 h), with ad libitum access to food (1.25% calcium, 1.06% phosphate,
CE-2, Clea Japan, Inc., Tokyo, Japan) andwater. Rats were then divided
in three groups: 1) the Sham group, whose animals were sham-
ovariectomized and received only vehicle (medium chain triglyceride,
MCT) after the procedure (n=8), 2) the OVX group, where animals
underwent standard ovariectomy but received only MCT after the
surgical procedure (n=8), and 3) the eldecalcitol group, where
animals underwent standard ovariectomy andwere given eldecalcitol
by gavage (n=8, 30 ng/kg, 5 times per week, Chugai Pharmaceutical
Co., Ltd., Tokyo, Japan). At 3 and 13 days prior to killing, tetracycline
(20 mg/kg BW) or calcein (8 mg/kg BW) was injected subcuta-
neously. Urine was collected over a twenty-four hour period after
the last administration of either eldecalcitol or vehicle.
Rats were perfused through the left ventricle with 4% paraformal-
dehyde diluted in 0.1 M phosphate buffer (pH 7.4) under anesthesia
with an intraperitoneal injection of chloral hydrate, and had their
femora and tibiae extracted, decalciﬁed and embedded in parafﬁn
as previously described [28]. Four μm-thick sections were cut and
stained with HE for histological analysis. Specimens were observed
under a Nikon Eclipse E800 microscope (Nikon Instruments Inc.
Tokyo, Japan). Light microscopic images were acquired with a digital
camera (Nikon DXM1200C, Nikon). For transmission electron mi-
croscopy (TEM), ﬁxed specimens were decalciﬁed, post-ﬁxed with
OsO4, dehydrated, and embedded in epoxy resin (Epon 812, Taab,
Berkshire, UK) as previously described [28]. Semi- and ultrathin-
sections were observed under light microscopy or under a TEM
(Hitachi H-7100, Hitachi Co., Tokyo, Japan) at 80 kV.Bone mineral density and assessment of bone resorption markers
Femoral bone mineral density (BMD) was measured by dual-
energy X-ray absorptiometry (DXA: DCS-600EX, Aloka, Tokyo, Japan).
Results are shown in milligrams per square centimeter. Urinary
creatinine (Cre) concentrations were measured with an automatic
analyzer (7170, Hitachi, Tokyo, Japan). Urinary deoxypylidinoline
(DPD) concentration wasmeasured using aMetra DPD EIA kit (Quidel
Corporation, San Diego, CA). Data were corrected for urinary Cre
concentration, and results are expressed in nmol/mmol.Immunohistochemistry and tartrate-resistant acid phosphatase (TRAP)
detection
Dewaxed parafﬁn sections were treated for endogenous peroxi-
dase inhibition with 0.3% H2O2 in phosphate buffered saline (PBS)
for 20 min and nonspeciﬁc staining blocking with 1% bovine serum
albumin in PBS (1% BSA-PBS) for 30 min at room temperature (RT).
Sections were incubated with 1) rabbit antisera against tissue
nonspeciﬁc alkaline phosphatase (ALP) [28,29], 2) mouse anti-rat
ED1 (AbD Serotec, Oxford, UK), and 3) rabbit anti-cathepsin K (Daiichi
Fine Chemical Co., Ltd., Toyama, Japan) for 2 h at RT, and then,
incubated with horseradish peroxidase (HRP)-conjugated anti-rabbit
or anti-mouse secondary antibodies (R&D System Inc., Minneapolis,
MN) for 1 h at RT. Immunoreactions were detected with 3,3′-
diaminobenzidine tetrahydrochloride (DAB, Dojindo Laboratories,
Kumamoto, Japan). A sequential approach was employed for the
cathepsin K/ED1 double immunostaining procedure. Cathepsin K
immunohistochemistry was performed as described above. ED-1
immunoreactivity was detected as described, only with goat ALP-
conjugated anti-mouse IgG (Sigma) as the second antibody andwith a
visualization procedure described previously [30]. For double detec-
tion of ALP/PCNA, immunostaining using anti-mouse PCNA (Onco-
gene Research products, San Diego, CA) was conducted, and a HRP-
conjugated second antibody was used to allow for visualization. Then,
ALP detection was conducted using an ALP-conjugated second
antibody as described above. TRAP-activity was detected as described
previously [28]. All sections were faintly counterstained with methyl
green.Von Kossa's staining
Undecalciﬁed semi-thin epoxy resin sections were incubated
with an aqueous solution of 5% silver nitrate (Wako Pure Chemical
Industries, Tokyo, Japan) for 60 min at RT under sunlight until they
took on a dark brown color. Following a distilled water rinse, sections
were incubated with a 5% sodium thiosulfate solution (Wako Pure
Chemical Industries) for 5 min. Sections were faintly stained with
toluidine blue for observation and image acquisition.Detection of apoptotic cells through TUNEL
For detection of apoptotic cells in the specimens, the “TACS 2TdT-
Blue Label In Situ Apoptosis Detection Kit” (TREVIGEN Inc., Gaithers-
burg, MD) for the terminal deoxynucleotidyl transferase-mediated
deoxyuridinetriphosphate nick end-labeling (TUNEL) method was
employed. Dewaxed sections were incubated with 1% proteinase
K (TREVIGEN Inc.) diluted 1:200 at 37 °C for 15 min, followed by
inhibition of the endogenous peroxidases at room temperature for
5 min. After treatment with TdT enzyme (dilution 1:50) at 37 °C for
1 h, sections were incubated with HRP-conjugated streptavidin at
room temperature for 15 min. Reaction was made visible with
the blue label solution provided in the kit.
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Fig. 1. Histological features of bone specimens from Sham, OVX and eldecalcitol groups
and femoral BMD values. Bone loss following ovariectomy is obvious (compare A to B).
Eldecalcitol effectively salvaged bone loss after ovariectomy (C) maintaining a bone
content similar to that of Sham specimens (compare to A). Panels D–F show highly
magniﬁed images of metaphyses. With regards to ALP expression as evaluated by
immunohistochemistry, difference among groups was very subtle (G, H, and I). J:
Femoral BMD ratiﬁed the histological data and showed similar values for Sham and
eldecalcitol groups. Bars A–C 1 mm, D–F 50 μm, and D–G 20 μm.
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Bone histomorphometrical parameters were quantiﬁed using the
ImagePro Plus 6.2 software (Media Cybernetics, Silver Spring, MD). For
determination of structural parameters, HE-stained parafﬁn sections
were used. For kinetic parameters, 10 μm-thick sections embedded in
glycol methacrylate (GMA) were stained with the Villanueva method
and observed under a ﬂuorescent microscope (Nikon Eclipse E800).
Images (region of interest — ROI: a 600 μm2 portion of metaphyseal
region, 400–1200 μm away from the growth plate and excluding the
cortical bone)wereobtained for all groups (n=8per group). Osteoclasts
were identiﬁed as TRAP-positive multinucleated cells attached to the
surface of trabecular bone. Osteoblasts were deﬁned as square- or cone-
shaped cells lining the surface of trabecular bone. Abbreviations and
calculationswere done according to the recommendationsof theASBMR
Histomorphometry Nomenclature Committee [31].
Quantiﬁcation of TUNEL-positive cells, cathepsin K-negative/ED-1
positive cells and ALP/PCNA-double positive cells
Images of TUNEL-positive cells, cathepsin K-negative/ED-1 positive
cells and ALP/PCNA-double positive cells (a 400 μm×400 μm square
portionofmetaphyseal region, 150 μmbelowthegrowthplate, excluding
the cortical bone)were taken fromeldecalcitol-injected andnon-injected
samples (n=8per group). Stained cells were countedwith the aid of the
ImagePro Plus 6.2 software (Media Cybernetics, Silver Spring, MD), and
the results are shown in cell number per μm2 of tissue area.
Statistical analysis
All statistical analyses were performed using Microsoft Excel 2003
Analysis ToolPak (Microsoft Corporation, Redmond, WA), with differ-
ences among groups being assessed by unpaired Student's t-tests
or LSD method, and considered statically signiﬁcant at pb0.05.
Results
Eldecalcitol rescues excessive bone loss after ovariectomy
The extent of bone loss following ovariectomywas evident after our
initial histological analysis (Figs. 1A, B, D and E) and conﬁrmed by both
BMD values (Fig. 1J) and obtained structural histomorphometrical data
(Table 1). Statistically signiﬁcant differenceswere found between Sham
and OVX groups for all structural parameters except for trabecular
thickness, which was nevertheless higher in that group. Eldecalcitol
successfully rescued the bone loss seen after ovariectomy (Figs. 1C, F),
with the treatment group showing histomorphometrical values similar
to thoseof the Shamgroup(Table 1). Interestingly, therewasnoobvious
differenceamong thegroupswith regards toALPactivity asevaluatedby
immunohistochemistry (Figs. 1G, H, and I). Osteoblastic and bone
formation parameters were enhanced in the OVX group accompanied
by increased bone resorption parameters (Table 1). However, femoral
BMD increased after eldecalcitol treatment in OVX animals, reaching
values similar to those obtained from the Sham group (Fig. 1J).
Focal bone formation “bone minimodeling”, after eldecalcitol
administration
Histological analysis of semithin epoxy sections from eldecalcitol-
treated specimens showed an ubiquitous presence of bone “buds” or
“boutons” (Figs. 2A–C). The images unveiled a “budding” or “bouton”
bone formation pattern characteristic of minimodeling, which is seen
when new bone is deposited on previously quiescent surfaces and
therefore features smooth cement lines (Figs. 2A–C). Eldecalcitol-
treated specimens revealed various bone buds labeled with contin-
uous lines of tetracycline and calcein (Fig. 2A), covered by matureosteoblasts (Fig. 2C). Despite this uncommon pattern of bone
formation characterized by the presence of smooth cement lines,
assessment of mineralization by von Kossa's staining ruled out the
possibility of defects in mineralization (data not shown). Moreover,
TEM imaging permitted the visualization of mature osteoblasts lying
on the bone “boutons” (Fig. 2D). Immunohistochemistry for ALP
and PCNA demonstrated that preosteoblasts were proliferating less
actively in the eldecalcitol group, when compared to the OVX group
(Figs. 2E–G; OVX, 10.06±3.84; Eldecalcitol, 3.59±2.48; pb0.005).
Therefore, eldecalcitol appears to inhibit preosteoblastic proliferation,
which may force osteoblast maturation.
Eldecalcitol rescues bone loss essentially by affecting osteoclastic and
resorption parameters
TRAP staining allowed for the identiﬁcation of a higher number of
osteoclasts in OVX samples when compared to Sham specimens
Table 1
Histomorphometric parameters in Sham, OVX and eldecalcitol groups.
INDEX GROUP
Sham
(n=8)
OVX
(n=8)
Eldecalcitol
(n=8)
Structural parameters
Bone volume (BV/TV, %) 23.78±9.12a 9.6±3.51 29.2±11.57a
Trabecular separation
(Tb. Sp, μm)
214.88±83.47a 548.56±176.37 190.89±50.92a
Trabecular number
(Tb. N, mm−1)
3.83±0.85a 1.79±0.51 3.82±0.55a
Trabecular thickness
(Tb. Th, μm)
60.55±12.04 52.98±7.62 75.53±24.15b
Osteoblast surface
(Ob. S/BS, %)
5.51±3.1b 11.85±5.22 4.44±3.13b
Osteoid surface (OS/BS, %) 8.71±4.89b 18.34±8.02 9.06±4.5b
Kinetic parameters
Bone formation rate, tissue
level (BFR/BS, μm3/μm2/d)
0.04±0.03b 0.08±0.04 0.04±0.01b
Mineral apposition rate
(MAR, μm/d)
1.43±0.21 1.29±0.08 1.19±0.07b
Mineralizing surface
(MS/BS, %)
6.24±3.39c 17.21±7.91 5.85±3.48c
Osteoclastic and bone resorption parameters
Number of mononuclear
osteoclasts (N. Mo. Oc/BS,
cells/mm)
0.61±0.25a 1.35±0.47 0.48±0.3a
Number of multinuclear
osteoclasts (N. Mu. Oc/BS,
cells/mm)
0.47±0.23a 1.32±0.52 0.54±0.39c
Number of osteoclasts
(N. Oc/BS, cells/mm)
1.08±0.46a 2.67±0.76 1.02±0.64a
Osteoclast surface
(Oc. S/BS, %)
3.22±1.65a 7.9±2.5 3.59±2.52c
Eroded surface (ES/BS, %) 28.7±9.33 37.59±7.02 17.41±11.09a
Data are expressed as mean±SD, p values determined by unpaired student's t test.
a pb0.005 vs. OVX.
b pb0.05 vs. OVX
c pb0.01 vs. OVX.
osteoblasts
osteoid
Sham OVX Eldecalcitol
osteoblasts
bone matrix
bone marrow
bone matrix
Eldecalcitol
B
A
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D
F G
trabecule
trabecule
bone marrow
Fig. 2. Bone minimodeling in a specimen treated with eldecalcitol. Eldecalcitol-treated
specimens revealed continuous tetracycline and calcein labeling on many bone buds
(white arrows in A). In a low magniﬁed image of toluidine blue staining, the “budding”
or “bouton” bone formation pattern can be seen (B). This pattern can be characterized
as minimodeling, since bone (asterisk) is laid out on top of smooth cement lines (white
arrows in C). TEM imaging (C) depicts mature osteoblasts lying on top of a bone
“bouton” whose normal osteoid appears to be mineralizing (inset, D). Despite the
presence of many mature osteoblasts, there is hardly any preosteoblastic cell layer
overlying mature osteoblasts (C, D). Panels E–G show double staining for ALP (blue
color) and PCNA (brown color) in Sham (E), OVX (F) and eldecalcitol-administered (G)
groups. Bars A–B 50 μm, C 20 μm, and D–G 10 μm.
338 P.H.L. de Freitas et al. / Bone 49 (2011) 335–342(Figs. 3A–B). After eldecalcitol administration, there were less TRAP-
positive osteoclasts (Fig. 3C), a ﬁnding veriﬁed by histomorphome-
trical analysis (Table 1). Highly magniﬁed light microscopy images
showed that eldecalcitol-treated specimens feature osteoclasts that
appear to have an inactive, ﬂattened morphology (compare Fig. 3D
to E). TEM imaging consistently showed large active osteoclasts
with well-developed rufﬂed borders in OVX specimens (Fig. 3F),
while ﬂattened, inactive osteoclasts with poorly developed rufﬂed
borders were a regular ﬁnding in samples from eldecalcitol-treated
rats (Fig. 3G). Also, eldecalcitol administration suppressed ovariecto-
my-induced increment of an important bone resorption marker,
urinary DPD (Fig. 3H).
Eldecalcitol administration increases the number of macrophages in the
bone marrow
ED1 immunohistochemistry revealed an increased number of
immunopositive cells in the marrow of specimens from the eldecalci-
tol group (compare Fig. 4A to B). To assess to what degree such
cells were committed to the osteoclastic lineage, double immunos-
taining for cathepsin K/ED1 was carried out and made evident the
distinction between macrophages and osteoclasts (Figs. 4C–D).
Higher-magniﬁed light microscopy revealed that the bone marrow
of eldecalcitol-treated specimens has a great number of macrophages
with inclusion bodies (Fig. 4E), while TEM further envisioned many
lysosomes in these macrophages (Fig. 4F). Quantiﬁcation of cathepsin
K-negative/ED1-positive cells identiﬁed a statistically signiﬁcant
increase after eldecalcitol administration when compared to OVX
group (Fig. 4G).Eldecalcitol administration does not increase apoptosis in the bonemarrow
In order to investigate whether the increased presence of macro-
phages in the marrow was due to enhanced apoptosis after eldecalcitol
administration,we conducted TUNEL staining. Quantiﬁcation of TUNEL-
               t
osteoclast
ruffled border
collagen fibrils
osteoclastosteoclast
Sham OVX Eldecalcitol
osteoclast
OVX Eldecalcitol
OVX Eldecalcitol
A
F
ED
CB
G
ruffled border
H
Sham OVX Eldecalcitol
p<0.001 p<0.001
N.S.
Fig. 3. Presence, morphology and function of osteoclasts in the different groups. TRAP staining shows higher numbers of osteoclasts in OVX samples compared to the other groups (A,
B and C). Toluidine blue-stained semithin sections from eldecalcitol-treated specimens feature osteoclasts that seem rather inactive and less exuberant when compared to OVX
osteoclasts (compare D to E). TEM imaging unveils large active osteoclasts with well-developed rufﬂed borders in OVX samples (F), while showing ﬂattened, quiescent osteoclasts in
eldecalcitol-treated specimens (G). Eldecalcitol administration suppressed ovariectomy-induced increase of urinary DPD (H). Bars A–C 50 μm, D–E 20 μm, and F–G 10 μm.
339P.H.L. de Freitas et al. / Bone 49 (2011) 335–342stained cells showed that the number of apoptotic cells is the lowest in
eldecalcitol group (Fig. 5A).
Discussion
After administering eldecalcitol or vehicle to OVX rats, our main
ﬁndings were: 1) with eldecalcitol administration, osteoblasts
accumulate and synthesize new bone on top of smooth cement lines
in process known as bone minimodeling; 2) eldecalcitol appears to
affect osteoblastic differentiation and activation instead of stimulating
preosteoblastic proliferation; 3) treatment with eldecalcitol lowers
osteoclast number and diminishes osteoclastic activity/functionality,
without promoting osteoclast apoptosis; and 4) eldecalcitol admin-
istration may favor the macrophage differentiation cascade on the
expense of cells that would otherwise become osteoclasts. Therefore,eldecalcitol indirectly promotes a bone formation process known
as minimodeling, but appears to exert its bone-protective effects
mainly by affecting osteoclastic number and function. It may do so by
favoring the macrophage lineage while hampering ﬁnal osteoclastic
differentiation, since there is an increased macrophage population
in the bone marrow of eldecalcitol-treated specimens that cannot be
explained by enhanced apoptosis.
In agreement with previous reports on the action of vitamin D
analogs [23,26,32,33], this experiment showed that eldecalcitol can
successfully prevent bone loss after ovariectomy. Our histological,
histomorphometrical and femoral BMD analyses did demonstrate the
recovery of bone structural parameters in OVX rats administered with
eldecalcitol (Table 1). Interestingly, neither osteoblast and osteoid
surface nor any of the kinetic bone parameters' values were positively
affected by eldecalcitol; in fact, the values obtained for eldecalcitol
cathepsin K 
ED1
ED1
A
E
DC
B
F
OVX Eldecalcitol
G
Sham OVX Eldecalcitol
mφ mφ
mφ
p<0.05N.S
N.S.
Ly
Ly
Ly
(red)
(brown)
Fig. 4. Findings after ED1 and cathepsin K/ED1 immunohistochemistry and ultrastruc-
tural analysis of the bone marrow of eldecalcitol-treated specimens. The abundant
presence of ED1-positive cells in the bone marrow of eldecalcitol-treated samples
(arrows, B) was an interesting ﬁnding, since ED1 is a marker for both macrophages and
osteoclasts (compare A to B). To rule out the possibility that these ED1-positive cells
were osteoclasts, or osteoclast precursors, we performed cathepsin K/ED1 double
immunohistochemistry to create a visual distinction between osteoclasts and macro-
phages. ED1/cathepsin K-positive cells (white arrows in C) are osteoclasts, which
invariably populate bone surfaces, while ED-1-positive/cathepsin K-negative cells
(black arrows in D) can be regarded as macrophages (compare C and D). Toluidine blue
staining of semithin epoxy sections of eldecalcitol-treated specimens demonstrates
macrophages (mϕ) populating the bone marrow (E). TEM imaging shows the ultra-
structure of a bone marrow macrophage (F) with its many lysosomes (Ly).
Quantiﬁcation of cathepsin K-negative/ED1-positive cells shows statistically signiﬁcant
higher numbers after eldecalcitol administrationwhen compared to the OVX group (G).
Bars A–D 50 μm, E 20 μm, and F 2 μm.
B
Sham OVX Eldecalcitol
A N.S. p<0.05
Fig. 5. TUNEL staining for assessment of apoptosis. Quantiﬁcation of TUNEL-stained
cells showed that the number of apoptotic cells is lowest in the eldecalcitol group (A).
In panel B, there is a schematic summary of the proposed mechanism of eldecalcitol
(EDR)'s action on bone cells: the drug appears to inhibit ﬁnal differentiation of
osteoclastic precursors, which may in turn become macrophages; it also seems to drive
osteoblastic differentiation and to promote bone minimodeling.
340 P.H.L. de Freitas et al. / Bone 49 (2011) 335–342and Sham groups were very similar. In that case, changes in the
pattern of ALP staining are not expected, as seen in Figs. 1G–I.
Enhanced ALP staining was anticipated, but not veriﬁed, in the OVX
group. ALP expression, while expressed consistently seen throughout
osteoblastic differentiation, has been demonstrated to be condition
sine qua non for mineralization as demonstrated in ALP knockout mice
[34]. OVX animals suffer from accelerated bone turnover, showing
stimulated osteoclastic bone resorption and reactive osteoblastic bone
formation with a net result of bone loss. Even though eldecalcitol
activates mature osteoblasts and induces minimodeling, the activated
osteoclastic status in OVX animals may conceal any surplus in boneformation. Osteoblasts may compensate for the abnormal bone
destruction by frantically synthesizing osteoid, while mineralization
seems to be slowed down. After ovariectomy, Parameters that refer to
non-mineralized bone matrix such as osteoid surface and mineraliz-
ing surface show two- and three-fold increases, respectively, when
compared to Sham animals. Osteoblasts in the OVX group, therefore,
may not show enhanced expression of ALP because their main
function, in a scenario of untamed bone destruction, is rapid bone
matrix synthesis, not its mineralization. The histological picture seen
after eldecalcitol treatment is quite different from the one obtained
with an intermittent PTH regimen, in which we showed the clear
proliferative and osteoblastic activation effects of that hormone [35].
Alternatively, Okuda et al. [23] have shown that ED-71, the former
denomination of eldecalcitol, was capable of promoting enhancement
of ALP activity and bone nodule formation in bone marrow cells in
vitro, where the inﬂuence of osteoclastic bone resorption does not
exist. Under our experimental circumstances, it seems that eldecalci-
tol drives osteoblastic differentiation in vivo with consequent bone
minimodeling without noticeable differences in the pattern of ALP
staining.
The histological data in this study unveiled the consistent presence
of a rather particular type of bone formation after eldecalcitol
treatment: bone minimodeling. Minimodeling is termed so because
magniﬁcation is needed to visualize it [36], and it basically consists of
bone formation not preceded by osteoclastic bone resorption with
cement lines that are typically smooth [37]. Minimodeling in bone has
been reported after treatment with bone anabolic agents like PTH [38]
and prostaglandin E2 [39]. It has been hypothesized that the
mechanism guiding minimodeling-based bone formation is the
resumption of osteoblastic activity of bone lining cells [40]. In
341P.H.L. de Freitas et al. / Bone 49 (2011) 335–342our histological samples, we did observe a dominant presence of
plump osteoblasts compared to that of resting bone lining cells in
eldecalcitol-treated specimens (Figs. 2C–D). The absence of numerical
data regarding the amount of minimodeling-based bone formation
and the number of active osteoblasts as opposed to bone lining cells
are limitations of this study. However, it is evident from the histology
shown here that eldecalcitol treatment fosters bone minimodeling.
In contrast with the effect of the drug upon osteoblastic cells
seen in our experimental setup, observations on the behavior and
morphology of osteoclastic cells have been more elusive of eldecalci-
tol's main mechanism of bone loss prevention. In our study,
osteoclastic, bone resorption parameters and urinary DPD have
demonstrated that eldecalcitol is an inhibitor of bone resorption, as
previous studies have reported for other vitamin D analogs [17,26].
Eldecalcitol administration lowered osteoclast numbers in OVX rats,
and more importantly, signiﬁcantly lowered the amount of eroded
surface (Table 1). Accordingly, our histological data showed inactive
osteoclasts on the bone surfaces of eldecalcitol-treated samples,
suggesting that not only was the drug able to bring osteoclastic
parameters close to those from the Sham group, but it also may have
affected the osteoclast's ability to disorganize the bone matrix. This
mechanism of action is different from that of bisphosphonates, which
drive osteoclastic apoptosis when given in concentrations above
100 μM [41]. Baldock et al. have shown that overexpression of VDR in
mature osteoblasts suppresses osteoclastogenesis [42], possibly by
an OPG-related mechanism [43]. Also, it has been suggested that
increased osteoblast maturation can reduce 1α,25-(OH)2D3-regulated
osteoclastogenesis in bone marrow/osteoblast co-culture [44]. This
postulation can be supported by the histological ﬁndings of
preosteoblasts with a lessened proliferative proﬁle in eldecalcitol-
administered specimens (Figs. 2E–G). It is possible that, by forcing
osteoblastic differentiation towards the mature phenotype, eldecalci-
tol indirectly suppresses cell-to-cell contact between osteoclastic
precursors/osteoclasts and preosteoblastic cells, thereby affecting
osteoclastogenesis and osteoclastic activity.
The increased number of cells of the macrophage phenotype in the
bone marrow of eldecalcitol-treated samples was another interesting
ﬁnding of our study. It is now common knowledge that the osteoclast
is a member of the monocyte/macrophage family and that ﬁnal
osteoclastic differentiation is inﬂuenced by many different molecules
[45]. 1α,25-(OH)2D3 stimulates osteoclast formation indirectly
through bone marrow stroma cells [46]. The hormone is regarded as
a fusion factor for monocytes/macrophages, as well [47]. Our results
have shown that the increase in macrophage numbers is not related
to increased apoptosis, which would implicate a need for more
phagocytic cells, and therefore indicated facilitated macrophage
differentiation by eldecalcitol. Based on our data, it is fair to infer
that complete osteoclastic differentiation is blocked somewhere along
the differentiation cascade; instead, the precursors might be guided
towards differentiating into the macrophage phenotype, probably
because of lessened interaction between preosteoblastic cells and
preosteoclasts.
In summary, our ﬁndings showed that eldecalcitol prevents
bone loss following ovariectomy in rats mainly by suppressing bone
resorption (Fig. 5E). The increased macrophage numbers seen in
eldecalcitol-treated specimens may be a reﬂection of a block in the
osteoclastic differentiation cascade. Bone minimodeling, although not
quantiﬁed, was ubiquitous in samples from the eldecalcitol group.
Taken together, the evidence presented here unveiled the histological
aspects of eldecalcitol's action upon bone, qualifying it as a promising
drug for the treatment of osteoporosis.
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